Gut microbiota–derived short‐chain fatty acids regulate group 3 innate lymphoid cells in HCC

Abstract

These findings suggested that modifying bacteria, changing SCFAs, reducing IL-17A-producing ILC3 infiltration, and combining with immune checkpoint inhibitors will contribute to the clinical treatment of HCC.